Kun Cheng

Title: Kun Cheng: Innovator in Crystalline Forms of Acalabrutinib

Introduction

Kun Cheng is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceuticals, particularly through his work on crystalline forms of Acalabrutinib. His innovative approach has led to advancements that may enhance the efficacy and stability of this important drug.

Latest Patents

Kun Cheng holds a patent for the crystalline forms of Acalabrutinib. This patent includes several specific crystalline forms, such as Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea. This patent represents a significant advancement in the formulation of Acalabrutinib, which is crucial for its therapeutic applications.

Career Highlights

Kun Cheng is associated with Apotex Inc., a leading global pharmaceutical company. His work at Apotex has allowed him to focus on innovative drug formulations and contribute to the development of new therapeutic options. His expertise in crystallization techniques has been instrumental in his research and development efforts.

Collaborations

Throughout his career, Kun Cheng has collaborated with several talented professionals, including Fabio E S Souza and Bahareh Khalili. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical formulations.

Conclusion

Kun Cheng's contributions to the field of pharmaceuticals, particularly through his patent on crystalline forms of Acalabrutinib, highlight his role as an innovator. His work continues to impact the development of effective therapeutic options in the pharmaceutical industry.